amphetamine has been researched along with Anankastic Personality in 3 studies
Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.
1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.
amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Amphetamine abuse is increasing worldwide, and the occurrence of amphetamine-induced (AI) psychiatric issues further complicates treatment." | 3.83 | The prevalence and clinical features of amphetamine-induced obsessive compulsive disorder. ( Alikhani, M; Bajoghli, H; Brand, S; Farnia, V; Holsboer-Trachsler, E; Juibari, TA; Karimi, AR; Shakeri, J; Tatari, F, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shakeri, J | 1 |
| Farnia, V | 1 |
| Karimi, AR | 1 |
| Tatari, F | 1 |
| Juibari, TA | 1 |
| Alikhani, M | 1 |
| Bajoghli, H | 1 |
| Holsboer-Trachsler, E | 1 |
| Brand, S | 1 |
| Wong, DF | 1 |
| Brasić, JR | 1 |
| Singer, HS | 1 |
| Schretlen, DJ | 1 |
| Kuwabara, H | 1 |
| Zhou, Y | 1 |
| Nandi, A | 1 |
| Maris, MA | 1 |
| Alexander, M | 1 |
| Ye, W | 1 |
| Rousset, O | 1 |
| Kumar, A | 1 |
| Szabo, Z | 1 |
| Gjedde, A | 1 |
| Grace, AA | 1 |
| Siever, LJ | 1 |
| Insel, TR | 1 |
| Hamilton, JA | 1 |
| Aloi, J | 1 |
| Murphy, DL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open Label, Proof-of-Principle, Pilot Study to Evaluate Pimavanserin for the Treatment of Motor and Behavioral Symptoms of Tourette Syndrome[NCT04794413] | Early Phase 1 | 10 participants (Actual) | Interventional | 2018-11-12 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for amphetamine and Anankastic Personality
| Article | Year |
|---|---|
Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET.
Topics: Adult; Amphetamine; Brain Mapping; Dopamine; Dopamine Agents; Dopamine Plasma Membrane Transport Pro | 2008 |
2 other studies available for amphetamine and Anankastic Personality
| Article | Year |
|---|---|
The prevalence and clinical features of amphetamine-induced obsessive compulsive disorder.
Topics: Adult; Amphetamine; Amphetamine-Related Disorders; Central Nervous System Stimulants; Cross-Sectiona | 2016 |
A comparison between the growth hormone responses to amphetamine and clonidine.
Topics: Adult; Amphetamine; Clonidine; Depressive Disorder; Growth Hormone; Humans; Obsessive-Compulsive Dis | 1985 |